Disorders of Lipid Metabolism
Autor G.V. Marinettien Limba Engleză Paperback – 3 feb 2012
Preț: 697.85 lei
Preț vechi: 734.58 lei
-5% Nou
Puncte Express: 1047
Preț estimativ în valută:
133.58€ • 140.22$ • 110.34£
133.58€ • 140.22$ • 110.34£
Carte tipărită la comandă
Livrare economică 30 ianuarie-13 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461595663
ISBN-10: 1461595665
Pagini: 244
Ilustrații: 240 p.
Dimensiuni: 152 x 229 x 13 mm
Greutate: 0.33 kg
Ediția:Softcover reprint of the original 1st ed. 1990
Editura: Springer Us
Colecția Springer
Locul publicării:New York, NY, United States
ISBN-10: 1461595665
Pagini: 244
Ilustrații: 240 p.
Dimensiuni: 152 x 229 x 13 mm
Greutate: 0.33 kg
Ediția:Softcover reprint of the original 1st ed. 1990
Editura: Springer Us
Colecția Springer
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
1 Disorders of Lipid Digestion and Absorption.- 1.1. Introduction to the Structures and Properties of Lipids.- 1.2. Digestion and Absorption of Lipids.- 1.3. Characteristics of Disorders of Lipid Digestion and Absorption.- References.- 2 Disorders of Fatty Acid Metabolism.- 2.1. General Aspects of Fatty Acid Metabolism.- 2.2. ? Oxidation of Fatty Acids.- 2.3. Disorders of Propionic Acid Metabolism.- 2.4. ? and ? Oxidation of Fatty Acids.- 2.5. Refsum’s Disease.- 2.6. Zellweger’s Syndrome.- 2.7. Ketogenesis, Ketosis, and Ketoacidosis.- 2.8. Synthesis of Fatty Acids.- 2.9. Essential Fatty Acid Deficiency.- References.- 3 Disorders of Excessive Alcohol Intake: Hypoglycemia, Fatty Liver, and Liver Cirrhosis.- 3.1. Introduction to the Biochemical Effects of Alcohol Intake.- 3.2. Metabolism of Alcohol.- 3.3. Effects of Alcohol Intake on Fatty Acid Metabolism.- 3.4. Alcoholic Hypoglycemia.- 3.5. Alcoholic Hepatitis and Liver Cirrhosis.- 3.6. Effects of Alcohol on the CNS.- 3.7. Effects of Acetaldehyde.- 3.8. Effects of Alcohol on the Heart.- 3.9. Alcohol-Drug Interactions.- 3.10. Alcohol Withdrawal Symptoms.- 3.11. Alcohol Intake and Heart Disease.- References.- 4 Disorders of Cholesterol Metabolism: Cholesterol Storage Diseases.- 4.1. Overall Cholesterol Balance in Humans.- 4.2. Synthesis of Cholesterol.- 4.3. Conversion of Cholesterol to Bile Acids.- 4.4. Abnormalities of Cholesterol Metabolism.- 4.5. Cholelithiasis (Gallstones).- References.- 5 Disorders of Lipoprotein Metabolism: Dyslipoproteinemias.- 5.1. Plasma Lipoproteins and Apoproteins: General Aspects.- 5.2. Structure and Function of Apoproteins.- 5.3. Metabolism of Lipoproteins.- 5.4. LDL, LDL Receptor, and HMGR.- 5.5. Pathogenesis of Hyperlipoproteinemias.- 5.6. Factors Leading to Hyperlipidemias.- 5.7.Mechanisms of Hyperlipidemias.- 5.8. Lipoprotein Metabolism in Diabetes.- 5.9. Hypolipoproteinemias.- References.- 6 Cholesterol, Lipoproteins, and Atherosclerosis.- 6.1. Atherosclerosis.- 6.2. Survey Studies: Cholesterol and CHD.- 6.3. Alcohol Intake and CHD.- 6.4. Drug Therapy for Hyperlipidemias.- 6.5. Postulated Mechanisms of Atherosclerosis.- References.- 7 Dietary Management of Elevated Blood Lipids.- 7.1. Dietary Lipids, Hyperlipidemia, and Heart Disease.- 7.2. Biochemical Effects of Polyunsaturated Fatty Acids.- 7.3. Platelet and Blood Vessel Prostaglandins Derived from Dietary Polyunsaturated Fatty Acids.- 7.4. Effects of Polyunsaturated Fatty Acids on Platelet Function.- 7.5. Platelet Lipid Composition.- 7.6. Platelet and Vascular Function.- 7.7. Mechanisms of Fatty Acid Effects.- 7.8. Possible Risks and Side Effects from Increased Amounts of Dietary Polyunsaturated Fatty Acids.- References.- 8 Drug Therapy for Hyperlipidemias: Lipid-Lowering Drugs and Antithrombic and Fibrinolytic Drugs.- 8.1. Lipid-Lowering Drugs.- 8.2. Combined Drug Therapy.- 8.3. Antithrombic Drugs.- 8.4. Fibrinolytic Drugs.- 8.5. Mechanisms of Action of Antithrombic Drugs.- 8.6. Arachidonic Acid Release Inhibitors.- 8.7. Drugs That Inhibit cAMP Formation in Platelets.- 8.8. Membrane-Active Drugs.- 8.9. Anticoagulants and Other Drugs.- 8.10. Antithrombic Drugs for Treatment of CHD.- References.- 9 Lung Surfactant Deficiency: Respiratory Distress Syndrome of the Newborn.- 9.1. Early History.- 9.2. Properties of DPPC.- 9.3. Lung Surfactant.- 9.4. Synthesis of Lung Surfactant Phospholipids.- 9.5. Hormonal Regulation of the Synthesis of Lung Surfactant.- 9.6. Therapy for RDS.- References.- 10 Sphingolipidoses: Gangliosidoses, Tay-Sachs Disease, and Sandhoff’s Disease.- 10.1. Early History.-10.2. Genetic Defects.- 10.3. Sphingolipids.- 10.4. Overview of the Sphingolipidoses.- 10.5. Therapeutic Approaches for the Sphingolipidoses.- References.